Chiome Bioscience Inc. (TYO:4583)

Japan flag Japan · Delayed Price · Currency is JPY
95.00
-3.00 (-3.06%)
May 12, 2026, 3:30 PM JST
Market Cap6.90B -19.2%
Revenue (ttm)593.29M -24.0%
Net Income-982.78M
EPS-14.47
Shares Out72.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume499,000
Average Volume447,940
Open98.00
Previous Close98.00
Day's Range95.00 - 98.00
52-Week Range95.00 - 168.00
Beta0.38
RSI32.70
Earnings DateMay 14, 2026

About Chiome Bioscience

Chiome Bioscience Inc. engages in the research and development of antibody drugs in Japan, Singapore, and internationally. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib system, a monoclonal antibody production technology that uses chicken immune cells to produce antibodies for drug discovery research. It also develops drugs under Phase I clinical trial, including ADCT-701, a humanized anti-dlk1 antibody for the treatment of solid tumors; CBA-1205, a humanized afucosylated anti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 53
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4583
Full Company Profile

Financial Performance

In 2025, Chiome Bioscience's revenue was 593.29 million, a decrease of -24.02% compared to the previous year's 780.81 million. Losses were -982.78 million, -3.72% less than in 2024.

Financial Statements